Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study

Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, Wenzel SE, Wilson AM, Small MB, Gopalan G, Ashton VL, Burden A, Hillyer EV, Kerkhof M, Pavord ID

Lancet Respir Med 2015; 3(11): 849–58.

By |September 13th, 2016|OPCRD|0 Comments

Predicting frequent COPD exacerbations using primary care data

Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB; Respiratory Effectiveness Group

Int J Chron Obstruct Pulmon Dis 2015; 10: 2439-50.

By |September 13th, 2016|OPCRD|0 Comments

Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice

Price D, Wilson AM, Chisholm A, Rigazio A, Burden A, Thomas M, King C

J Asthma Allergy 2016; 9: 1-12.

By |September 13th, 2016|OPCRD|0 Comments

Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study

Chrystyn H, Price DB, Molimard M, Haughney J, Bosnic-Anticevich S, Lavorini F, Efthimiou J, Shan D, Sims E, Burden A, Hutton C, Roche N

BMC Pulm Med 2016; 16(1):12.

By |September 13th, 2016|OPCRD|0 Comments

Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting

Westerik JA, Carter V, Chrystyn H, Burden A, Thompson SL, Ryan D, Gruffydd-Jones K5, Haughney J, Roche N, Lavorini F, Papi A, Infantino A,Roman-Rodriguez M11, Bosnic-Anticevich S, Lisspers K, Ställberg B, Henrichsen SH, van der Molen T, Hutton C, Price DB

J Asthma 2016; 53(3): 321-9.

By |September 13th, 2016|OPCRD|0 Comments

Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational

Gruffydd-Jones K, Brusselle G, Jones R, Miravitlles M, Baldwin M, Stewart R, Rigazio A, Davis E, Keininger DL, Price D

NPJ Prim Care Respir Med 2016; 26: 16002.

By |September 13th, 2016|OPCRD|0 Comments

Cost-effectiveness of asthma step-up therapy as an increased dose of extrafine-particle inhaled corticosteroid or add-on long-acting beta2-agonist

Roche N, ColiceG, Israel E, Martin RJ, Dorinsky PM, Postma DS, Guilbert TW, Grigg J, van Aalderen WMC, Barion F, Hillyer EV, Thomas V, Burden A, McQueen RB, Price DB

Pulm Ther 2016; 2: 73-89.

By |September 13th, 2016|OPCRD|0 Comments

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler

Price DB, Colice G , Israel E , Roche N , Postma DS , Guilbert TW , van Aalderen WMC, Grigg J, Hillyer EV , Thomas V, Martin RJ

ERJ Open Res 2016; 2(2).

By |September 13th, 2016|OPCRD|0 Comments

Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry

Sweeney J, Patterson CC, Menzies-Gow A, Niven RM, Mansur AH, Bucknall C, Chaudhuri R, Price D, Brightling CE, Heaney LG; on behalf of the British Thoracic Society Difficult Asthma Network

Thorax 2016; 71(4): 339-46.

By |September 13th, 2016|OPCRD|0 Comments

Multi-component assessment of chronic obstructive pulmonary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in international primary care data sets

Jones RC, Price D, Chavannes NH, Lee AJ, Hyland ME, Ställberg B, Lisspers K, Sundh J, van der Molen T, Tsiligianni I; UNLOCK Group of the IPCRG

NPJ Prim Care Respir Med 2016; 26: 16010.

By |September 13th, 2016|OPCRD|0 Comments